Johnson & Johnson

US · JNJ #19 by market cap Listed 1970 AI Rating C 56

275.23 -3.20 -1.15%

Collector offline (last heartbeat: 16001s ago) · 2026-09-04 19:59

Pre-market 275.00 -1.23%

After-hours 276.53 +0.47%

Overnight 278.74 +0.11%

Mkt cap: 663.28B
P/E (TTM): 31.93
P/B: 7.81
EPS: 11.03
Div yield: 1.90%
52W pos: 95%

Revenue annual, last 8 years

Latest year +6.05% YoY

Margins

Gross margin: 67.88%
Operating margin: 27.17%
Net margin: 28.46%

Key ratios & quality

Enterprise value: 691.11B
PEG ratio: 2.23

PEG uses trailing P/E against the 3-year net income growth rate (14.32%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG."

Income statement

Line item	2018	2019	2021	2021	2022	2023	2024	2025
Revenue	81.58B	82.06B	82.58B	78.74B	79.99B	85.16B	88.82B	94.19B
Gross profit	54.49B	54.50B	54.16B	55.34B	55.39B	58.61B	61.35B	63.94B
Selling & admin expenses	22.54B	22.18B	22.08B	20.12B	20.25B	21.51B	22.87B	23.68B
Research & development	10.78B	11.36B	12.16B	14.28B	14.14B	15.09B	17.23B	14.67B
Operating profit	21.18B	20.97B	19.91B	20.94B	21.01B	22.01B	21.25B	25.60B
Pretax profit	18.00B	17.33B	16.50B	19.18B	19.36B	15.06B	16.69B	32.58B
Tax	2.70B	2.21B	1.78B	1.38B	2.99B	1.74B	2.62B	5.78B
Net profit	15.30B	15.12B	14.71B	20.88B	17.94B	35.15B	14.07B	26.80B
Basic EPS	6	6	6	8	7	14	6	11
Diluted EPS	5.61	5.63	5.51	7.81	6.73	13.72	5.79	11.03

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	21.89B	23.74B	23.99B	24.56B	24.06B	25.31B
Gross profit	14.54B	16.12B	16.69B	16.60B	15.96B	17.26B
Selling & admin expenses	5.11B	5.89B	5.92B	6.75B	6.03B	6.43B
Research & development	3.23B	3.52B	3.67B	4.25B	3.53B	3.65B
Operating profit	6.20B	6.71B	7.10B	5.59B	6.40B	7.17B
Pretax profit	13.63B	6.49B	7.49B	4.97B	5.99B	6.75B
Tax	2.63B	954.00M	2.34B	-150.00M	755.00M	1.21B
Net profit	11.00B	5.54B	5.15B	5.12B	5.24B	5.53B
Basic EPS	5	2	2	2	2	2
Diluted EPS	4.54	2.29	2.12	2.10	2.14	2.27

Balance sheet

Line item	2018	2019	2021	2021	2022	2023	2024	2025
Total current assets	46.03B	45.27B	51.24B	60.98B	55.29B	53.50B	55.89B	55.62B
Cash & ST investments	19.69B	19.29B	25.19B	31.61B	22.28B	22.93B	24.52B	20.10B
Inventory	8.60B	9.02B	9.34B	10.39B	10.27B	11.18B	12.44B	14.19B
Total assets	152.95B	157.73B	174.89B	182.02B	187.38B	167.56B	180.10B	199.21B
Total current liabilities	31.23B	35.96B	42.49B	45.23B	55.80B	46.28B	50.32B	54.13B
Short-term debt	2.80B	1.20B	2.63B	3.77B	12.76B	3.45B	5.98B	8.50B
Long-term debt	27.68B	26.49B	32.64B	29.99B	26.89B	25.88B	30.65B	39.44B
Total liabilities	93,202,000,000.00	98,257,000,000.00	111,616,000,000.00	107,995,000,000.00	110,574,000,000.00	98,784,000,000.00	108,614,000,000.00	117,666,000,000.00
Total equity	59.75B	59.47B	63.28B	74.02B	76.80B	68.77B	71.49B	81.54B
Retained earnings	--	--	--	--	--	--	--	--

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	71.55B	54.50B	54.61B	55.62B	59.17B	59.77B
Cash & ST investments	38.78B	18.88B	18.56B	20.10B	22.05B	20.76B
Inventory	12.66B	13.41B	14.15B	14.19B	14.58B	15.14B
Total assets	193.67B	193.39B	192.82B	199.21B	200.89B	201.06B
Total current liabilities	56.90B	54.18B	50.87B	54.13B	57.72B	54.90B
Short-term debt	13.90B	11.53B	6.39B	8.50B	17.46B	11.69B
Long-term debt	38.36B	39.24B	39.41B	39.44B	37.53B	37.34B
Total liabilities	115,562,000,000.00	114,916,000,000.00	113,539,000,000.00	117,666,000,000.00	119,708,000,000.00	116,090,000,000.00
Total equity	78.11B	78.47B	79.28B	81.54B	81.19B	84.97B
Retained earnings	--	--	--	--	--	--

Cash flow

Line item	2018	2019	2021	2021	2022	2023	2024	2025
Operating cash flow	22.20B	23.42B	23.54B	23.41B	21.19B	22.79B	24.27B	24.53B
Depreciation & amortization	6.93B	7.01B	7.23B	7.39B	6.97B	7.49B	7.34B	7.50B
Free cash flow	18.53B	19.92B	20.19B	19.76B	17.19B	17.78B	18.06B	19.31B
Dividends paid	-9.49B	-9.92B	-10.48B	-11.03B	-11.68B	-11.77B	-11.82B	-12.38B
Stock buybacks / issuance	-5.87B	-6.75B	-3.22B	-3.46B	-6.04B	-813.00M	-2.43B	-5.95B
Ending cash balance	18.11B	17.31B	13.99B	14.49B	14.13B	21.86B	24.11B	19.71B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	4.17B	3.88B	9.17B	7.31B	2.51B	8.62B
Depreciation & amortization	1.77B	1.94B	1.78B	2.01B	2.00B	1.96B
Free cash flow	3.37B	2.48B	8.00B	5.47B	1.47B	7.30B
Dividends paid	-2.99B	-3.13B	-3.13B	-3.13B	-3.13B	-3.23B
Stock buybacks / issuance	-2.13B	0	-1.90B	-1.92B	-4.03B	-221.00M
Ending cash balance	38.47B	18.58B	18.23B	19.71B	21.69B	20.42B

Returns & efficiency

Line item	2018	2019	2021	2021	2022	2023	2024	2025
ROE %	25.51	25.36	23.97	30.41	23.79	48.29	20.06	35.03
ROA %	9.86	9.73	8.85	11.70	9.71	19.81	8.09	14.13
ROIC %	16.90	17.01	15.93	20.35	15.84	32.36	13.17	22.50
5-year avg ROE %	19.09	19.62	20.04	21.45	25.81	30.37	29.31	31.52
EBIT margin %	23.29	21.50	20.22	24.48	23.17	18.59	19.64	35.62
FCF / sales %	22.71	24.27	24.45	21.07	18.10	20.88	20.33	20.50
Current ratio	1.47	1.26	1.21	1.35	0.99	1.16	1.11	1.03
Quick ratio	1.08	0.94	0.91	1.12	0.70	0.91	0.86	0.77
Debt / assets	51.01	46.57	55.73	45.60	51.61	42.65	51.24	58.78
LT debt / equity	46.33	44.55	51.57	40.51	35.01	37.63	42.87	48.36
Interest coverage	18.91	55.49	83.07	125.46	79.71	20.51	23.10	34.55
Revenue CAGR (3Y) %	5.20	4.51	2.61	-1.17	-0.85	1.03	4.10	5.60
Net income CAGR (3Y) %	-0.24	-2.95	124.52	10.92	5.87	33.68	-12.33	14.32
FCF CAGR (3Y) %	4.79	8.62	4.33	2.16	-4.80	-4.15	-2.95	3.97

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	29.45	30.21	33.62	35.03	26.42	25.74
ROA %	11.93	12.10	13.54	14.13	10.66	10.67
ROIC %	18.29	18.49	21.61	22.50	15.84	16.05
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	30.68	31.10	35.16	35.62	26.96	26.76
FCF / sales %	20.79	18.09	20.27	20.50	18.07	22.70
Current ratio	1.26	1.01	1.07	1.03	1.03	1.09
Quick ratio	0.96	0.68	0.71	0.77	0.77	0.73
Debt / assets	66.90	64.69	57.77	58.78	67.73	57.71
LT debt / equity	49.10	50.00	49.71	48.36	46.22	43.95
Interest coverage	34.09	33.48	36.24	34.55	25.00	25.90
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

Revenue breakdown most recent period

Business

Innovative Medicine64.73%

MedTech35.27%